Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.48 |
| ▸ | CTSG | P08311 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.41 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.41 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27441071 | 0.83 | PRSS1 (0.69) | HRH4PRSS1CTSGCTRB1CMA1 | |
| SCHEMBL12913502 | 0.83 | PRSS1 (0.64) | PRSS1CTSGCTRB1CMA1CYP1A2 | |
| SCHEMBL15576223 | 0.79 | PRSS1 (0.59) | HRH4PRSS1CTSGCTRB1CMA1 | |
| SCHEMBL6997866 | 0.79 | RAB9A (0.66) | HRH4PRSS1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL6653240 | 0.79 | CA1 (0.48) | PRSS1CTSGCTRB1CMA1CYP1A2 | |
| SCHEMBL6773139 | 0.78 | PRSS1 (0.50) | HRH4PRSS1CTSGCTRB1CMA1 | |
| SCHEMBL20201195 | 0.77 | TDP1 (0.62) | CYP3A4ALDH1A1MAPK1L3MBTL1MAPT | |
| SCHEMBL24526798 | 0.76 | ALDH1A1 (0.56) | HRH4PRSS1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL6991219 | 0.75 | HRH4 (0.47) | HRH4PRSS1CTSGCTRB1CMA1 | |
| SCHEMBL7906637 | 0.74 | PRSS1 (0.52) | HRH4PRSS1CTSGCTRB1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1201740-C | Medicine for treating intermittent claudication containing pyrroloazepine * compound | DAIICHI SUNTORY LTD (JP) | 2005-05-18 | — | — | CN | disclosed |
| EP-1071427-B1 | INTERMITTENT CLAUDICATION THERAPEUTIC DRUGS COMPRISING PYRROLOAZEPINES | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-6713634-B2 | SEROTONIN RECEPTOR ANTAGONIST | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| US-20030166926-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 2003-09-04 | — | — | US | disclosed |
| US-6489473-B2 | FOR THERAPY AND PROPHYLAXIS OF ISCHEMIC HEART DISEASES SUCH AS ANGINA PECTORIS, ARRHYTHMIA, MYOCARDIAL INFARCTION, CONGESTIVE HEART FAILURE, CEREBRAL INFARCTION AND CEREBRAL SEQUELAE AFTER SUBARACHNOID HEMORRHAGE, HYPERTENSION | SUNTORY LIMITED (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020072515-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 2002-06-13 | — | — | US | disclosed |
| EP-0807632-B1 | PYRROLOAZEPINE DERIVATIVES | SUNTORY LTD (JP) | 2002-04-17 | — | — | EP | disclosed |
| US-6288056-B1 | ADMINISTERING TO TREAT ATHEROSCLEROSIS IN LEG ARTERIES | SUNTORY LIMITED (JP) | 2001-09-11 | — | — | US | disclosed |
| US-6258805-B1 | TREATMENT OF BRAIN DISORDERS AND HYPERTENSION | SUNTORY LIMITED (JP) | 2001-07-10 | — | — | US | disclosed |
| CN-1297351-A | Medicine for treating intermittent claudication containing pyrroloazepine * compound | SUNTORY LTD (JP) | 2001-05-30 | — | — | CN | disclosed |
| US-5962448-A | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| EP-0807632-A1 | PYRROLOAZEPINE DERIVATIVES | SUNTORY LIMITED (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072515-A1 | Pyrroloazepine derivatives | TPH2, HTR2A, HTR2C | HRH4 318/4885PRSS1 607/4885CTSG 3510/4885 |
| US-20030166926-A1 | Pyrroloazepine derivatives | TPH2, HTR2A, HTR2C | HRH4 333/4885PRSS1 657/4885CTSG 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.